Novel magnetic vortex nanorings/nanodiscs: Synthesis and theranostic applications
Liu Xiao-Lia),b), Yang Yonga), Wu Jian-Pengb), Zhang Yi-Fanb), Fan Hai-Mingb), Ding Jun†a)
Department of Materials Science and Engineering, Faculty of Engineering, National University of Singapore, 7 Engineering Drive 1, Singapore 117574, Singapore
School of Chemical Engineering, Northwest University, Xi’an 710069, China

Corresponding author. E-mail: msedingj@nus.edu.sg

*Project supported by the National Natural Science Foundation of China (Grant Nos. 21376192 and 81571809), the Research Fund for the Doctoral Program of Higher Education of China (Grant No. 20126101110017), and MOE AcRF Tier 2-MOE2011-T2-1-043 and A-Star SERC 1321202068.

Abstract

Recent discoveries in the synthesis and applications of magnetic vortex nanorings/nanodiscs in theranostic applications are reviewed. First, the principles of nanomagnetism and magnetic vortex are introduced. Second, methods for producing magnetic vortex nanorings/nanodiscs are presented. Finally, theranostic applications of magnetic vortex nanorings/nanodiscs are addressed.

PACS: 75.75.–c; 75.75.Cd; 87.61.–c; 87.53.Jw
Keyword: magnetic nanorings/nanodiscs; vortex domain; magnetic resonance imaging; magnetic hyperthermia
1. Introduction

Magnetic nanoparticles have been widely used in a variety of applications, especially in biomedical fields such as magnetic resonance imaging (MRI), [15] magnetic separation, [610] magnetic hyperthermia therapy, [1116] and drug delivery.[1720] With the growing concern for the prevention and treatment of cancer, research into MRI diagnosis and magnetic hyperthermia therapy, which are commonly referred to as “ theranostics, ” [15] has accelerated. One key issue is to improve the magnetic properties of theranostic agents to achieve early detection and efficient treatment for cancer.[21] Already, superparamagnetic nanoparticles (SPIOs) have been widely investigated as theranostic agents, and some have been commercially available for many years.[2225] It is widely accepted in this field that a stable suspension for biomedical applications can be achieved only by using SPIOs. The non-superparamagnetic nanoparticles possess remanance which may lead to undesired agglomeration. Unfortunately, small SPIOs with low saturation magnetization have limits in theranostic applications. Designing and optimizing the size, composition, shape, and surface of magnetic nanoparticle coatings is reported to improve the performance of theranostic agents.[4, 2637] However, in the development of these theranostic agents, their efficiency has reached its limit, because their saturation magnetization is comparable to that of bulk materials.[38, 39] In addition, introducing other magnetic elements (such as Co and Mn) to increase the magnetic moment may raise concerns about toxicity. Seeking a new class of theranostic agents to replace SPIOs might be an alternative way to solve this problem, but such research encountered a bottleneck in the past. Thus, finding a new approach to design and develop magnetic nanoparticles with good suspension and improved magnetic properties as well as significantly enhanced theranostic performance is becoming important and urgent.

At nanoscale, size and shape effects play important roles in the magnetic properties of nanostructures.[4042] The size effect results in single-domain ferromagnetic/ferrimagnetic and superparamagnetic nanoparticles, which have attracted intense interest due to their extraordinary potential for biomedical applications. When shape changes at a nanoscale, new magnetization configurations appear. Different shapes prefer different magnetic domain structures for energy minimization, leading to tremendous variation in magnetic properties. To fully exploit the size and shape effects at nanoscale and realize optimum properties for targeted applications, the understanding of nanomagnetism, control of magnetic properties and development of related synthetic methods are of great importance.

The discovery of magnetic vortex-domain nanorings/nanodiscs has brought a novel approach for forming a good suspension and improving magnetic properties. To achieve a stable vortex-domain structure, the dimensions of the nanorings/nanodiscs must be carefully manipulated. For example, outer diameter, height and inner-to-outer diameter ratio are the key parameters for nanorings to be located in the exact region of the stable vortex area.[43] In particular, this unique magnetic structure endows nanorings/nanodiscs with negligible or decreased remanence and coercivity — greatly reducing dipole– dipole interactions and enabling good colloidal stability — but with much higher saturation magnetization and larger hysteresis loops than SPIOs. Under an external field, nanorings/nanodiscs undergo magnetic moment reversal processes and move along the field direction rapidly. Therefore, nanorings/nanodiscs with magnetic vortex-domain structure have emerged as a new material for theranostic applications.

In this review, we aim to provide an overview of recent developments in the chemical synthesis of magnetic vortexdomain nanorings/nanodiscs and developments in their applications. We first introduce the general principles of nanomagnetism and magnetic vortex-domain. We then discuss chemical synthesis of magnetic vortex-domain nanorings/nanodiscs. Toward the end, the potential applications of the nanorings/nanodiscs in biomedicine are highlighted.

2. General principles

Characterization of magnetic nanoparticles might address many magnetic properties. The basic properties are the types of response to a magnetic field (including ferromagnetic/ferrimagnetic/superparamagnetic, paramagnetic and antiferromagnetic).[44, 45] The magnetization curve characterizes this magnetic behavior of magnetic nanoparticles. For ferromagnetic/ferrimagnetic materials, the magnetic properties are typically of interest, such as saturation magnetization (Ms), remanence magnetization (Mr) and coercivity (Hc) can be obtained from the hysteresis loop (Fig.  1(a) and Fig.  1(d)). Figure  1(b) illustrates the dependence of coercivity on particle size. To minimize its magnetostatic energy, a ferromagnetic/ferrimagnetic particle needs to possess multiple magnetic domain structures. For particles smaller than a certain critical value, the energy required to create a domain wall is greater than the demagnetizing energy, enforcing a single-domain state. In this state, coercivity reaches a maximum at critical size, associated with the transition from multi-domain to the single domain. Further decreasing particle size results in a steep decrease of the Hc due to the assistance of thermal energy kBT (kB and T are the Boltzmann constant and temperature) in the switching process.[42] When particle size is reduced to a level where the magnetic anisotropy energy (KV) (K and V are the effective anisotropy constant and the nanoparticle volume) is much smaller than kBT, the spins rotate freely, without any external field. Such a nanoparticle is said to be superparamagnetic. As shown in Fig.  1(c), the MH curve of SPIOs shows no hysteresis. The forward and backward magnetization curves coincide completely and the area is almost negligible, indicating the anhysteretic nature. Magnetic nanoparticles in a superparamagnetic state do not tend to agglomerate, enabling suspension of the particles. Most experimental work in this field to date has used SPIOs. However, SPIOs’ weak magnetic interaction offsets their Ms.[30] Moreover, the usefulness of SPIOs suffers from surface effects, due to their high specific surface, which also offsets Ms, because of surface spin disorder in this case.[46] In addition, due to the decreased saturation magnetization, high magnetic fields, which may harm the human body, are required to manipulate these nanoparticles. Conversely, if magnetic particles with high saturation magnetization are fabricated, agglomeration may occur, owing to the large Mr. As shown in Figs.  1(c) and 1(d), under an applied magnetic field, the magnetic moment of the domains of ferromagnetic/ferrimagnetic particles and single-domain superparamagnetic particles are aligned. After removal of the applied magnetic field, ferromagnetic/ferrimagnetic particles maintain a net magnetization.

Fig.  1. (a) A typical hysteresis loop of a ferromagnetic/ferrimagnetic material. (b) Schematic illustration of the dependence of coercivity on particle size. (c) and (d) Typical hysteresis loops of a superparamagnetic nanomaterial and a ferromagnetic/ferrimagnetic nanomaterial. Under a magnetic field, the magnetic moments of the domains of ferromagnetic particles and single-domain superparamagnetic particles are aligned. After removal of the magnetic field, ferromagnetic particles maintain a net magnetization.

Magnetic vortex structures offer a new opportunity to achieve stable suspension and high saturation magnetization simultaneously. The hysteresis loop of a magnetic vortex nanoring is shown in Fig.  2(d). Due to the enclosed domain without stray fields, the Mr and Hc of magnetic vortex nanorings are close to zero. At the same time, in comparison with SPIOs, the magnetic vortex nanoring, larger in size, has a much higher Ms. This makes magnetic vortex nanostructures a promising candidate for diverse biomedical applications.

Fig.  2. (a)– (c) Observed remanence states of the magnetite nanorings within the vortex region of the ground state phase diagram at β = (a) 0.4, (b) 0.6, (c) 0.8.[43] Reprinted with permission from Ref.  [43]; Copyright 2012, AIP Publishing, LLC. (d)– (e) Magnetic states during switching when field is parallel to nanorings[43] and nanodisc[59] The cartoons are schematic diagrams of the corresponding domain structures. The unit 1  Oe = 79.5775  A/m. Reprinted with permission from Ref.  [43], copyright 2012, AIP Publishing, LLC. Reprinted with permission from Ref.  [59], © 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

The flux-closure vortex domain structure, where the spins align circularly, is a common magnetic state in magnetic nanorings/nanodiscs and has been intensively studied.[4760] In particular, the vortex-domain structure is sensitive to nanoring dimensions.[43] Our group has performed three-dimensional (3D) Landau– Liftshitz– Gilbert (LLG) micromagnetic simulations for magnetite nanorings. Figures  2(a)– 2(c) illustrate the observed remanence states of the magnetite nanorings within the vortex region of the ground state phase diagram at β = 0.4, 0.6 and 0.8 (β = Din/Dout) with the applied magnetic field along the x direction. The symbols represent computed points. We concluded that only the few areas highlighted by dashed lines were stable vortex areas.

Under an external magnetic field, the magnetic vortex state transforms into another state, which is closely related to the geometric shape of the nanomaterials.[47, 48] Figures  2(d) and 2(e) provide examples of reversal processes in magnetic nanorings and nanodiscs, simulated by Yang et al. For magnetic vortex-domain nanorings, the hysteresis loop is typically of a two-step magnetization reversal process involving an onion-to-vortex transition and then a transition from vortex to the reverse onion state.[43, 61, 62] As illustrated in Fig.  2(d), at H = 0 (vortex state), the magnetization circulates around the ring without stray field. As H increases, a new magnetic domain with opposite chirality nucleates. When H is larger than the switching field Hs, the onion state appears with two opposite head-to-head domain walls. Figure  2(e) presents a domain evaluation of a nanodisc. Obviously, at H = 0, the transition occurs from saturation state (i) to the c-state (ii). As H increases, a vortex core moves in from the edge of the nanodisc and forms a vortex state (iii). When H further increases, the vortex core moves gradually toward the opposite edge. The nanodisc is saturated until the vortex core disappears (iv). In contrast to magnetic vortex-domain nanodiscs with high energy vortex core, the vortex state in rings is a stable magnetic configuration. Based on the theory simulation of magnetic vortex-domain colloid, Fan et al. were first to propose a colloid of magnetic vortex nanorings for biomedical applications.[43, 63, 64] The MH curve (Fig.  2(d)) reveals there is no remanence for magnetic vortex nanorings. For fields sweeping from positive to negative saturation, the onion state maintains at remanence and the transition from onion to vortex state occurs abruptly at a certain field. The vortex state leads to weak magnetic interactions of nanorings that can be utilized to facilitate a magnetic nanoring suspension. The unique vortex structure and high saturation magnetization can provide strong local field inhomogeneity and large hysteresis, resulting in an extremely large relaxivity in MRI and extremely large specific absorption rate (SAR) in magnetic hyperthermia, respectively. In addition, a dispersion consisting of vortex nanorings can provide a fast, strong response under relatively small external field to meet the increasing demands of biological applications.

3. Fabrication of magnetic vortex-domain nanorings/nanodiscs

Controllable synthesis of magnetic nanorings/discs is a key for forming a stable vortex-domain structure and pursuing its biomedical applications. The prevailing strategy for preparing magnetic nanorings/discs is the solvothermal method.[54, 6568]

Fig.  3. (a) (top) Typical synthesis of magnetic nanorings; (bottom) SEM image and HRTEM of prepared Fe3O4 nanorings; inset is a selected area electron diffraction (SAED) image[64] Reprinted with permission from Ref.  [64], © 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. (b) (top) Schematic illustration for the synthesis of Fe3O4 nanodiscs; [59] (bottom) SEM image and HRTEM of prepared Fe3O4 nanodiscs; inset is an SAED image[59] Reprinted with permission from Ref.  [59], © 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Single-crystalline magnetic nanorings were fabricated by hydrothermal growth of hematite (α -Fe2O3) nanorings and post reduction. Fan et al.[65, 66] reported that α -Fe2O3 nanorings could be formed through hydrothermal treatment of FeCl3 in the presence of NH4H2PO4. In this case, NH4H2PO4 could covalently adsorb onto α -Fe2O3 crystal planes parallel to the c axis and react with α -Fe2O3 to form a dissolvable complex in solution, which can serve as either a surfactant to induce anisotropic growth or an etching agent. As a result, hollow nanorings can be obtained during this coordination-assisted dissolution process. By varying the concentration of FeCl3 and NH4H2PO4, the size of hematite nanorings can be modulated. Figure  3(a) shows the overall scheme for the synthesis of spinel MFe2O4 nanorings. The insets are optical images of Fe3O4 and α -Fe2O3 nanorings. The obtained α -Fe2O3 nanorings can be further transformed into cubic spinel magnetite Fe3O4, maghemite γ -Fe2O3 or ferrite MFe2O4 (M = Co, Mn, Ni, Cu) by using a thermal transformation process, without changing their size and shape. Both the scanning electron microscope (SEM) and high-resolution transmission electron microscope (HRTEM) analysis reveal that the as-prepared Fe3O4 nanorings have uniform size and shape and a single crystal nature.

High quality Fe3O4 nanodiscs are fabricated by a twostep chemical synthesis, as shown in Fig.  3(b). Chen et al.[68] were first to report an alcohol-thermal reaction for the fabrication of uniform α -Fe2O3 nanodiscs. Hexagonal α -Fe2O3 nanodiscs have been successfully grown via a simple ethanolthermal route in the presence of ethanol with the addition of acetate sodium. Acetate anions in acetate sodium can covalently adsorb onto α -Fe2O3 (0001) surfaces and control the growth along the specific direction. The size can be finely tuned by the selective use of alcohol solvent with an increasing presence of carbon atoms in the linear alkyl chain. α -Fe2O3 nanodiscs are successfully converted into Fe3O4 nanodiscs by a hydrogen-wet reduction method. Using this method, high quality Fe3O4 nanodiscs are fabricated as shown in Fig.  3(b) (bottom).

4. The applications of vortex-domain nanorings/nanodiscs
4.1. Ferrimagnetic vortex-domain nanorings as T2-weighted contrast agent for diagnostics

Early and accurate diagnosis of diseases is very important, because it makes the treatments simpler and more effective. Unfortunately, many types of cancers are still very difficult to detect until their late stages.[6971] MRI is one of the most powerful medical diagnosis tools for visualizing biological tissues, the images of which are produced by the difference of the nuclear magnetic relaxation of water protons in the body. This technique can provide images with excellent anatomical details based on the soft tissue contrast and realtime monitoring manner.[19, 7274] To improve the sensitivity, magnetic nanoparticles are employed as contrast agents to increase the difference between pathogenic targets and normal tissues.[75] In other words, the presence of a contrast agent modifies the relaxation rate of surrounding protons and, therefore, changes the signal contrast. There are two types of contrast agents, positive (T1) contrast agents and negative (T2 and ) contrast agents. T1 contrast agents shorten the spin-lattice relaxation time of protons (T1 relaxation time) in the surroundings and generate a bright image; T2 contrast agents shorten the spin– spin relaxation times (T2 relaxation time) leading to signal reduction, that is, a dark image.[76] The efficiency of the contrast agent is quantified through the relaxation rate R = 1/T (s− 1) and the normalized relaxivity: r = R/concentration (mM− 1· s− 1). The higher the relaxivity, the better the contrast effect.

Due to the magnetic inhomogeneity induced by their strong magnetic moment, magnetic nanoparticles are typically T2 agents.[77] For example, SPIOs such as Ferumoxsil are commercial T2 contrast agents. On the basis of a quantum mechanical outer-sphere theory, the T2 relaxivity of iron oxide nanoparticles can be given by[78, 79]

where γ is the proton gyromagnetic ratio, V* , Ms, and a are the volume fraction, saturation magnetization, and radius of a magnetic nanoparticle core, respectively, D is the diffusivity of water molecules surrounding the magnetic nanoparticles and L is the thickness of an impermeable surface coating. According to this equation, the T2 relaxivity of iron oxide nanoparticles increases with the magnetization and the size of iron oxide cores if the total amount of iron, V* , is constant.

SPIOs with size below 20  nm have low saturation magnetization and susceptibility, which directly results in low performance in applications. Moreover, the relatively small size of SPIOs makes it difficult to retain their stoichiometry, size uniformity and magnetism during the complex protocol for water-soluble nanoparticles, which in turn leads to rather poor performance of the T2 relaxivity effect.[63] In this case, Fan et al.[63] reported that ferrimagnetic vortex-domain nanorings (FVIOs) with a superior shape-induced vortex magnetic property (Fig.  4(b)) and tunable size (70  nm– 200  nm in outer diameter) are expected to provide significant enhancement of an MR signal, which may overcome the drawbacks of conventional SPIO imaging agents. The MRI tests of magnetic vortex nanorings were performed using quantum dot (CdSe/ZnS) capped ferrimagnetic vortex-state iron oxide nanorings (QD-FVIO) (Fig.  4(a)). Figure  4(c) shows a qualitative comparison of -weighted spin-echo MRI of FVIO and commercial Ferucarbotran regarding the varied echo time. Obviously, compared with Ferucarbotran, QD-FVIOs result in significantly darker images at the designated echo time. The MR relaxivities of QD-FVIOs and Ferucarbotran are presented in Table  1. The values and ratios of QD-FVIOs are almost 4-fold and two orders larger than those of the commercial Ferucarbotran, respectively. Previous studies reported that the value strongly depends on the inhomogeneity of the local field surrounding the magnetic core, which corresponds to the relative volume fraction, magnetic moment and susceptibility of magnetic core. Hence, because of its special ring shape and magnetic moment switching process (from vortex to onion), QD-FVIOs possess both high relative volume fraction and susceptibility, which result in the extremely large value. In addition, the susceptibility difference between the inner and outer surface of FVIOs could result in the field inhomogeneity, which may also contribute to the enhancement of value. Overall, MRI measurements show that FVIO nanoring can significantly enhance -weighted MRI signals and have potential for cancer imaging applications.

Fig.  4. (a) Schematic illustration of water-dispersible QD-FVIOs. (b) Hysteresis loops of QD-FVIOs at 300  K. (c) In vitro weighted MRI of QD-FVIOs in 2% agarose and commercial ferucarbotran in water.[63] Reprinted with permission from Ref.  [63], Copyright (2010) American Chemical Society.

Table 1. MR relaxivities of QD-FVIOs and Commercial Ferucarbotran at 1.5  T[63] Reprinted with permission from Ref.  [63]. Copyright (2010) American Chemical Society.
4.2. Ferrimagnetic vortex-domain nanorings as mediators for anti-tumor therapeutics

Magnetic hyperthermia is a promising therapeutic tool for malignant tumor treatment by converting electromagnetic energy into heat using magnetic nano-mediators.[80, 81] This is based on the evidence that cancer cells are more sensitive than normal cells to temperatures higher than 42  ° C.[82] Such therapeutic capability is evaluated by SAR. The higher the SAR value, the greater the efficiency. The aim is to enhance the SAR of nano-mediators with a lower dosage. SPIOs are widely used in magnetic hyperthermia investigations because of their superparamagnetism, stable suspension and large surface area.[83, 84] However, magnetic nanoparticles possess low saturation magnetization and susceptibility, which in turn has affected its performance in applications. In addition to currently available SPIOs, the difficulty in striking a balance between having a good suspension and improved magnetic properties presents a challenging obstacle for the development of high-performance magnetic nanoparticle-based therapeutic agents.

FVIOs possess a ferromagnetic vortex-domain structure with negligible remanence and coercivity that can greatly reduce dipole– dipole interactions and enable good colloidal stability, but they have much higher saturation magnetization than SPIOs and a larger hysteresis loop.

The first magnetic hyperthermia test of magnetic vortex nanorings was performed using PEG (Mw = 5000  Da) capped FVIO. It demonstrated that an FVIO suspension is very efficient for thermal induction. Figure  5(a) shows a comparison of FVIOs and Resovist at 400  kHz. It is clear that FVIOs have far greater conversion efficiency than Resovist has. The highest SAR of FVIOs is 3050  W· g− 1 Fe at 400  kHz and 740  Oe, which is one order of magnitude higher than that of Resovist (106  W· g− 1). The high SAR values clearly indicate the excellent heating capability of FVIOs in comparison with single-domain Fe3O4 nanoparticles. The significantly superior heat generation ability of FVIO suspensions is likely related to a stable magnetic vortex-domain structure, a vortexto- onion magnetization reversal process, large hysteresis loss and a relatively large Ms. Theoretically, the heat induced by magnetic nano-mediators is proportional to the area of their hysteresis loop. Simulated hysteresis loops from an LLG micromagnetism simulation show strong angle-dependence due to shape anisotropy of FVIOs (Fig.  5(b)). Then an in vivo anti-tumor experiment was performed. Figure  5(c) shows schematics of magnetic hyperthermia treatment of a tumor in a tumor-bearing nude mouse xenografted with breast cancer cells (MCF-7). Magnetic nanoparticles were directly injected into the tumor of a mouse and an AC magnetic field (37.5 kHz; 400  Oe) was applied for 10 min. It was found that the tumor was eliminated by day 40 after treatment, by measuring the tumor volume (Fig.  5(d)). For comparison, when commercial SPIOs with the same treatment conditions were used to treat the mice, the tumors were not eliminated in 40  days. FVIO suspensions have demonstrated remarkable anti-tumor efficiency in mice without any associated severe toxic effect. The unique vortex-to-onion magnetization reversal process allows FVIOs to possess negligible remanence and significantly superior hysteresis loss, which not only promotes colloid stability but also maximizes the SAR.

Fig.  5. (a) Comparison of SAR for FVIOs and Resovist in different fields. The frequency is at 400  kHz. (b) Simulated hysteresis loops along different directions. Inset shows the switching field (Hs) along different directions. (c) Schematics showing the effect of magnetic hyperthermia treatment on tumor cells in a mouse model. (d) Nude mice xenografted with breast cancer cells (MCF-7) before treatment (upper row, dotted circle) and 40 days after treatment (lower row) with untreated control, Resovist hyperthermia and FVIOs hyperthermia, respectively.[64] Reprinted with permission from Ref.  [64], © 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

4.3. Ferrimagnetic vortex nanodiscs as mediators for magnetic hyperthermia therapeutics

In addition to the FVIOs, the Fe3O4 nanodiscs with vortex domain structure were also successfully fabricated and their hyperthermia properties were investigated. As shown in Fig.  6(a), ring-like magnetic flux can be observed in the nanodisc, which implies the existence of a vortex domain structure. From the simulated spin configuration nanodisc, it could be seen that the majority of spins align circularly in the plane of the disc and the center spin points out of plane, forming a typical vortex domain structure. Based on the domain structures, the hysteresis loops are simulated. Figure  6(b) provides the simulated hysteresis loop. The result is similar with nanorings. It is clear that the hysteresis loop changes significantly at different orientations, implying nanodiscs also have shape-anisotropy. Before measuring magnetic hyperthermia of Fe3O4 nanodiscs, the heat dissipation due to the hysteresis loss can be computed by[35, 85]

where μ is vacuum permeability, f is the frequency (488  kHz) of the alternating current (AC) field and M is the magnetization.

Through the above method, the SARs of nanodiscs in aqueous suspension and in agarose gel (5%) are 4659  W/g and 3017  W/g, respectively. The SAR values match very well with the experimental value of about 4925  W/g in water and 2818  W/g in gel. The excellent agreement between the experimental and calculated SAR values indicates that the SAR value of a nanodisc is strongly related to its orientation. As illustrated in Fig.  6(d), parallel alignment of nanodiscs results in a much higher SAR value than random orientation. In an AC field, nanodiscs in aqueous suspension flip and stir the water, thus converting the field energy into kinetic energy of the surrounding carrier. This study may open a new window for “ flipping” based heating seeds for high efficiency magnetic hyperthermia.

Fig.  6. (a) Magnetic domain structure of nanodisc. (b) Simulated hysteresis loops along different directions. (c) Comparison of SAR values between simulation and experiment in gel and water suspension. (d) Illustration of different orientations of nanodiscs in the gel and water suspension during magnetic hyperthermia measurement.[59] Reprinted with permission from Ref.  [59]; © 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Kim et al.[4] also reported novel cancer-treatment strategies using the magnetic vortex properties of magnetic vortex nanodiscs. As reported, the MD-mAb particles, created by combining gold-permalloy (Ni80Fe20) microdiscs and antihuman-IL13α 2R antibody (mAb), were used to mark N10 glioma cells, which in turn formed MDs-mAb-cell complexes. In an external low frequency AC field, nanodiscs with an unstable vortex core move reciprocally, creating an oscillation which transmits a mechanical force to the cell. Such a mechanical process will repeatedly apply pressure to the membrane of each N10 glioma cell until it shrinks and cracks, ultimately inducing programmed cell death of cancer cells (Fig.  7). To eliminate the influence of thermal effects, an extremely weak AC field (amplitude lower than 100  Oe, frequencies below 60  Hz) is applied, while cell solution temperature is always kept below 22  ° C. After applying the field to the N10 glioma for 10 minutes, cancer cells were significantly destroyed, while the surrounding normal tissue was only mildly damaged, as the applied AC field is weak and the application time is short. This research provides a new way of thinking in the treatment of cancer.

Fig.  7. The concept of targeted magneto mechanical cancer-cell destruction using disc-shaped magnetic particles possessing a spin-vortex ground state.[52] Reprinted with permission from Ref.  [52], copyright © 2009; rights managed by Nature Publishing Group.

5. Summary and perspective

Exceptional progress has been achieved in synthesis, vortex-domain structure control, and biomedical applications of magnetic vortex nanorings/nanodiscs, as described in this review. Magnetic vortex nanorings/nanodiscs are new platforms for theranostic applications. Chemical synthesis of magnetic nanorings/nanodiscs with vortex domain structure has progressed enormously. Both in vitro and in vivo studies have demonstrated their potential as diagnostic and therapeutic agents. However, several problems still require considerable work to be solved before magnetic vortex nanorings/nanodiscs are fully established for clinical translation. For example, synthesis of magnetic vortex nanorings/nanodiscs with very small size (10  nm– 50  nm) is still challenging. Producing different shapes of nanostructures with vortex-domain magnetic structure is a big problem that needs to be solved. Magnetic vortex domain nanostructure is expected to be functionalized with targeting ligands so that the cellular uptake is more targetable and controllable. The biodistribution, targeting efficiency, toxicity, biodegradability and clearance of magnetic vortex domain nanostructures also need to be studied further. In depth understanding of the magnetic vortex domain will provide a guideline to produce magnetic vortex nanostructures for other applications, such as thermosensitive drug release for cancer treatment. It is expected that magnetic vortex domain structure will be widely applied in magnetic, biomedical and nanotechnology fields.

Reference
1 Hu F Q, Wei L, Zhou Z, Ran Y L, Li Z and Gao M Y 2006 Adv. Mater. 18 2553 DOI:10.1002/(ISSN)1521-4095 [Cited within:1]
2 Yu J, Yang C, Li J, Ding Y, Zhang L, Yousaf M Z, Lin J, Pang R, Wei L, Xu L, Sheng F, Li C, Li G, Zhao L and Hou Y 2014 Adv. Mater. 26 4114 DOI:10.1002/adma.v26.24 [Cited within:1]
3 Liu D, Wu W, Ling J, Wen S, Gu N and Zhang X 2011 Adv. Funct. Mater. 21 1498 DOI:10.1002/adfm.v21.8 [Cited within:1]
4 Lee J H, Huh Y M, Jun Y W, Seo J W, Jang J T, Song H T, Kim S, Cho E J, Yoon H G, Suh J S and Cheon J 2007 Nat. Med. 13 95 DOI:10.1038/nm1467 [Cited within:2]
5 Yang H, Zhang C, Shi X, Hu H, Du X, Fang Y, Ma Y, Wu H and Yang S 2010 Biomaterials 31 3667 DOI:10.1016/j.biomaterials.2010.01.055 [Cited within:1]
6 Carinelli S, Mart’i M, Alegret S and Pividori M I 2015 New Biotechnol DOI:10.1016/j.nbt.2015.04.002 [Cited within:1]
7 Haun J B, Castro C M, Wang R, Peterson V M, Marinelli B S, Lee H and Weissleder R 2011 Biomaterials 3 71ra16 DOI:10.1126/scitranslmed.3002048 [Cited within:1]
8 Yavuz C T, Mayo J T, William W Y, Prakash A, Falkner J C, Yean S, Cong L, Shipley H J, Kan A, Tomson M, Natelson D and Colvin V L 2006 Science 314 964 DOI:10.1126/science.1131475 [Cited within:1]
9 Gu H, Xu K, Xu C and Xu B 2006 Chem. Commun. 9 941 [Cited within:1]
10 Bao J, Chen W, Liu T, Zhu Y, Jin P, Wang L, Liu J, Wei Y and Li Y 2007 ACS Nano 1 293 DOI:10.1021/nn700189h [Cited within:1]
11 Hergt R, Dutz S, Müller R and Zeisberger M 2006 J. Phys. : Condens. Matter 18 S2919 DOI:10.1088/0953-8984/18/38/S26 [Cited within:1]
12 Kumar C S and Mohammad F 2011 Adv. Drug. Deliver. Rev. 63 789 DOI:10.1016/j.addr.2011.03.008 [Cited within:1]
13 Laurent S, Dutz S, Häfeli U O and Mahmoudi M 2011 Adv. Colloid Interface 166 8 [Cited within:1]
14 Yoo D, Lee J H, Shin T H and Cheon J 2011 Accounts Chem. Res. 44 863 DOI:10.1021/ar200085c [Cited within:1]
15 Ho D, Sun X and Sun S 2011 Accounts Chem. Res. 44 875 DOI:10.1021/ar200090c [Cited within:1]
16 Hao R, Xing R, Xu Z, Hou Y, Gao S and Sun S 2010 Adv. Mater. 22 2729 DOI:10.1002/adma.201000260 [Cited within:1]
17 Arruebo M, Fernández-Pacheco R, Ibarra M R and Santamar’ia J 2007 Nano Today 2 22 DOI:10.1016/S1748-0132(07)70170-6 [Cited within:1]
18 Dobson J 2006 Drug. Dev. Res. 67 55 DOI:10.1002/(ISSN)1098-2299 [Cited within:1]
19 Sun C, Lee J S and Zhang M 2008 Adv. Drug. Deliv. Rev. 60 1252 DOI:10.1016/j.addr.2008.03.018 [Cited within:1]
20 Son S J, Reichel J, He B, Schuchman M and Lee S B 2005 J. Am. Chem. Soc. 127 7316 DOI:10.1021/ja0517365 [Cited within:1]
21 Liu X L and Fan H M 2014 Curr. Opin. Chem. Eng. 4 38 DOI:10.1016/j.coche.2013.12.010 [Cited within:1]
22 Frimpong R A and Hilt J Z 2010 Nanomedicine 5 1401 DOI:10.2217/nnm.10.114 [Cited within:1]
23 Xie J, Huang J, Li X, Sun S and Chen X 2009 Curr. Med. Chem. 16 1278 DOI:10.2174/092986709787846604 [Cited within:1]
24 Guo S, Li D, Zhang L, Li J and Wang E 2009 Biomaterials 30 1881 DOI:10.1016/j.biomaterials.2008.12.042 [Cited within:1]
25 Kim D K, Mikhaylova M, Wang F H, Kehr J, Bjelke B, Zhang Y, Tsakalakos T and Muhammed M 2003 Chem. Mater. 15 4343 DOI:10.1021/cm031104m [Cited within:1]
26 Fortin J P, Wilhelm C, Servais J, Ménager C, Bacri J C and Gazeau F 2007 J. Am. Chem. Soc. 129 2628 DOI:10.1021/ja067457e [Cited within:1]
27 Lee N, Choi Y, Lee Y, Park M, Moon WK, Choi SH and Hyeon T 2012 Nano Lett. 12 3127 DOI:10.1021/nl3010308 [Cited within:1]
28 Guardia P, Di Corato R, Lartigue L, Wilhelm C, Espinosa A, Garcia-Hernand ez M and Pellegrino T 2012 ACS Nano 6 3080 DOI:10.1021/nn2048137 [Cited within:1]
29 Jang J T, Nah H, Lee J H, Moon S H, Kim M G and Cheon J 2009 Angew. Chem. Int. Ed. 121 1260 DOI:10.1002/ange.200805149 [Cited within:1]
30 Lee J H, Jang J T, Choi J S, Moon S H, Noh S H, Kim J W and Cheon J 2011 Nat. Nanotechnol. 6 418 DOI:10.1038/nnano.2011.95 [Cited within:1]
31 Duan H, Kuang M, Wang X, Wang YA, Mao H and Nie S 2008 J. Phys. Chem. C 112 8127 DOI:10.1021/jp8029083 [Cited within:1]
32 Tong S, Tong S, Hou S, Zheng Z, Zhou J and Bao G 2010 Nano Lett. 10 4607 DOI:10.1021/nl102623x [Cited within:1]
33 Liu X L, Fan H M, Yi J B, Yang Y, Choo E S G, Xue J M and Ding J 2012 J. Mater. Chem. 22 8235 DOI:10.1039/c2jm30472d [Cited within:1]
34 Tromsdorf U I, Bigall N C, Kaul M G, Bruns O T, Nikolic M S, Mollwitz B and Weller H 2007 Nano Lett. 7 2422 DOI:10.1021/nl071099b [Cited within:1]
35 Noh S H, Na W, Jang J T, Lee J H, Lee E J, Moon S H and Cheon J 2012 Nano Lett. 12 3716 DOI:10.1021/nl301499u [Cited within:1]
36 Liu X L, Choo S G E, Ahmed A S, Zhao L Y, Yang Y, Ramanujan R V, Xue J M, Fan D D, Fan H M and Ding J 2014 J. Mater. Chem. B 2 120 DOI:10.1039/C3TB21146K [Cited within:1]
37 Liu X L, Wang Y T, Ng C T, Wang R, Jing G Y, Yi J B, Yang J, Bay B H, Yung L Y, Fan D D, Ding J and Fan H M 2014 Adv. Mater. Inter. 1300069 1 [Cited within:1]
38 Vergés M A, Costo R, Roca A G, Marco J F, Goya G F, Serna C J and Morales M P 2008 J Phys. D: Appl. Phys. 41 134003 DOI:10.1088/0022-3727/41/13/134003 [Cited within:1]
39 Lu H M, Zheng W T and Jiang Q 2007 J Phys. D: Appl. Phys. 40 320 DOI:10.1088/0022-3727/40/2/006 [Cited within:1]
40 Lau J W and Shaw J M 2011 J. Phys D: Appl. Phys. 44 303001 DOI:10.1088/0022-3727/44/30/303001 [Cited within:1]
41 Margeat O, Dumestre F, Amiens C, Chaudret B, Lecante P and Respaud M 2005 Prog. Solid Stat. Chem. 33 71 DOI:10.1016/j.progsolidstchem.2005.11.002 [Cited within:1]
42 Lacroix L M, Ho D and Sun S 2010 Curr. Top. Med. Chem. 10 1184 DOI:10.2174/156802610791384207 [Cited within:2]
43 Yang Y, Liu X L, Yi J B, Yang Y, Fan H M and Ding J 2012 J. Appl. Phys. 111 044303 DOI:10.1063/1.3684963 [Cited within:4]
44 Cullity B D and Graham C D 2011 Introduction to Magnetic Materials(Wiley IEEE Press) ISBN: 978-1-118-21149-6 [Cited within:1]
45 Jun Y W, Choi J S and Cheon J 2007 Chem. Commun. 12 1203 [Cited within:1]
46 Martnez B, Obradors X, Balcells L, Rouanet A and Monty C 1998 Phys. Rev. Lett. 80 181 DOI:10.1103/PhysRevLett.80.181 [Cited within:1]
47 Cowburn R P, Koltsov D K, Adeyeye A O, Welland M E and Tricker D M 1999 Phys. Rev. Lett. 83 1042 DOI:10.1103/PhysRevLett.83.1042 [Cited within:2]
48 Li S P, Peyrade D, Natali M, Lebib A, Chen Y, Ebels U, Buda L D and Ounadjela K 2001 Phys. Rev. Lett. 86 1102 DOI:10.1103/PhysRevLett.86.1102 [Cited within:1]
49 Shinjo T, Okuno T, Hassdorf R, Shigeto K and Ono T 2000 Science 289 930 DOI:10.1126/science.289.5481.930 [Cited within:1]
50 Podbielski J, Giesen F and Grundler D 2006 Phys. Rev. Lett. 96 167207 DOI:10.1103/PhysRevLett.96.167207 [Cited within:1]
51 Wachowiak A, Wiebe J, Bode M, Pietzsch O, Morgenstern M and Wiesendanger R 2002 Science 298 577 DOI:10.1126/science.1075302 [Cited within:1]
52 Kim D H, Rozhkova E A, Ulasov L V, Bader S D, Rajh T, Lesniak M S and Novosad V 2009 Nat. Mater. 9 165 DOI:10.1038/nmat2591 [Cited within:1]
53 He K, Smith D J and McCartney M R 2010 J. Appl. Phys. 10709D307 [Cited within:1]
54 Jia C J, Sun L D, Luo F, Han X D, Heyderman L J, Yan Z G, Yan C H, Zheng K, Zhang Z, Takano M, Hayashi N, Eltschka M, Kläui M, Rüdiger U, Kasama T, Gontard L C, Dunin-Borkowski R E, Tzvetkov G and Raabe J 2008 J. Am. Chem. Soc. 130 16968 DOI:10.1021/ja805152t [Cited within:1]
55 Neudecker I, Kläui M, Perzlmaier K, Backes D, Heyderman L J, Vaz C A F, Bland J A C, Rüdiger U and Back C H 2006 Phys. Rev. Lett. 96 057207 DOI:10.1103/PhysRevLett.96.057207 [Cited within:1]
56 Kläui M, Jubert P O, Allenspach R, Bischof A, Bland J A C, Faini G, Rüdiger U, Vaz C A F, Vila L and Vouille C 2005 Phys. Rev. Lett. 95 026601 DOI:10.1103/PhysRevLett.95.026601 [Cited within:1]
57 Rothman J, Kläui M, Lopez-Diaz L, Vaz C A F, Bleloch A, Bland J A C, Cui Z and Speaks R 2001 Phys. Rev. Lett. 86 1098 DOI:10.1103/PhysRevLett.86.1098 [Cited within:1]
58 Lua S Y H, Kushvaha S S, Wu Y H, Teo K L and Chong T C 2008 Appl. Phys. Lett. 93 122504 DOI:10.1063/1.2989135 [Cited within:1]
59 Yang Y, Liu X, Lv Y, Herng T S, Xu X, Xia W, Zhang T, Fang J, Xiao W and Ding J 2015 Adv. Funct. Mater. 25 812 DOI:10.1002/adfm.201402764 [Cited within:1]
60 Tanigaki T, Takahashi Y, Shimakura T, Akashi T, Tsuneta R, Sugawara A and Shindo D 2015 Nano Lett. 15 1309 DOI:10.1021/nl504473a [Cited within:1]
61 Lopez-Diaz L, Kläui M, Rothman J and Bland J A C 2002 J. Magn. Magn. Mater. 242 553 [Cited within:1]
62 Kazakova O, Hanson M, Blixt A M and Hjörvarsson B 2003 J. Magn. Magn. Mater. 258 348 [Cited within:1]
63 Fan H M, Olivo M, Shuter B, Yi J B, Bhuvaneswari R, Tan H R, Xing G C, Ng C T, Liu L, Lucky S S, Bay B H and Ding J 2010 J. Am. Chem. Soc. 132 14803 DOI:10.1021/ja103738t [Cited within:3]
64 Liu X L, Yang Y, Ng C T, Zhao L Y, Zhang Y, Bay B H, Fan H M and Ding J 2015 Adv. Mater. 27 1939 DOI:10.1002/adma.v27.11 [Cited within:1]
65 Fan H M, You G J, Li Y, Zheng Z, Tan H R, Shen Z X, Tang S H and Feng Y P 2009 J. Phys. Chem. C 113 9928 DOI:10.1021/jp9020883 [Cited within:2]
66 Fan H M, Yi J B, Yang Y, Kho K W, Tan H R, Shen Z X, Ding J, Sun X W, Olivo M C and Feng Y P 2009 ACS Nano 3 2798 DOI:10.1021/nn9006797 [Cited within:1]
67 Lu J, Jiao X, Chen D and Li W 2009 J. Phys. Chem. C 113 4012 DOI:10.1021/jp810583e [Cited within:1]
68 Chen L Q, Yang X F, Chen J, Liu J, Wu H, Zhan H, Liang C and Wu M 2010 Inorg. Chem. 49 8411 DOI:10.1021/ic100919a [Cited within:2]
69 Cancer: Key Facts. Retrieved 18th December 2013, from http://www.who.int/mediacentre/factsheets/fs297/en/ [Cited within:1]
70 Sailor M J and Park J H 2012 Adv. Mater. 24 3779 DOI:10.1002/adma.v24.28 [Cited within:1]
71 Nguyen K T 2011 J. Nanomed. Nanotechnol. 2 5 [Cited within:1]
72 Deng C L, Poggio M, Mamin H J, Rettner C T and Rugar D 2009 Proc. Natl. Acad. Sci. USA 106 1313 DOI:10.1073/pnas.0812068106 [Cited within:1]
73 Weissleder R and Pittet M J 2008 Nature 452 580 DOI:10.1038/nature06917 [Cited within:1]
74 Jun Y W, Lee J H and Cheon J 2008 Angew. Chem. Int. Ed. 47 5122 DOI:10.1002/anie.v47:28 [Cited within:1]
75 Qiao R R, Yang C H and Gao M Y 2009 J. Mater. Chem. 19 6274 DOI:10.1039/b902394a [Cited within:1]
76 Kim B H, Lee N, Kim H, An K, Park Y I, Choi Y, Shin K, Lee Y, Kwon S G, Na H B, Park J G, Ahn T Y, Kim Y W, Moon W K, Choi S H and Hyeon T 2011 J. Am. Chem. Soc. 133 12624 DOI:10.1021/ja203340u [Cited within:1]
77 Huh Y M, Jun Y, Song H T, Kim S, Choi J, Lee J H, Yoon S, Kim K S, Shin J S, Suh J S and Cheon J 2005 J. Am. Chem. Soc. 127 12387 DOI:10.1021/ja052337c [Cited within:1]
78 Gillis P, Moiny F and Brooks R A 2002 Magn. Reson. Med. 47 257 DOI:10.1002/(ISSN)1522-2594 [Cited within:1]
79 Brooks R A, Moiny F and Gillis P 2001 Magn. Reson. Med. 45 1014 DOI:10.1002/(ISSN)1522-2594 [Cited within:1]
80 Jordan A, Wust P, Fahling H, John W, Hinz A and Felix R 1993 Int. J. Hyperthermia 9 51 DOI:10.3109/02656739309061478 [Cited within:1]
81 Rosensweig R E 2002 J. Magn. Magn. Mater. 252 370 DOI:10.1016/S0304-8853(02)00706-0 [Cited within:1]
82 Hamdan S 2013 International Journal of Chemical, Environmental & Biological Sciences 1 191 DOI:10.1002/rcm.7220 [Cited within:1]
83 Gupta A K and Gupta M 2005 Biomaterials 26 3995 DOI:10.1016/j.biomaterials.2004.10.012 [Cited within:1]
84 Paul A 2004 Nat. Biotechnol. 22 47 DOI:10.1038/nbt927 [Cited within:1]
85 Carrey J, Mehdaoui B and Respaud M 2011 J. Appl. Phys. 109 083921 DOI:10.1063/1.3551582 [Cited within:1]